XXXX and @entity5 : which consequences in terms of disease management?

@entity1 @entity308 @entity0 @entity1313 @entity5 @entity73 @entity1307 @entity2728 @entity2727
OBJECTIVES: The aim of this review is to stress the importance of @entity73 in @entity5 survivors, and to discuss the way of assessing and managing these troubles in clinical practice. METHOD: Original studies and reviews reporting the effect of @entity5 and chemotherapy on cognition and published since January 2000 were selected from the Medline(  ) database using 'cognition' or 'cognitive function' and ' @entity5 ' as subject headings. RESULTS: Main reports concerned @entity1 with @entity0 or @entity1 with @entity1313 . Overall, chemotherapy was found to be associated with subtle and transient @entity73 , which were detectable only with neuropsychological testing and affected most particularly memory, concentration and speed of information processing. Some factors associated with the @entity1 , like @entity308 , may favor @entity73 , while the role of others, like age or educational level, remains to be defined. Screening of @entity1 at risk remains limited due to the lack of standardized neuropsychological tests in clinical oncology practice. Few studies have addressed the benefits of interventional strategies but @entity2727 , @entity2728 and @entity1307 , as well as rehabilitation in @entity1 , have shown encouraging results. Formal studies assessing the value of a multidisciplinary approach to detect and manage @entity73 must be recommended. CONCLUSION: @entity73 induced by @entity5 or the treatment represents a real challenge in clinical practice. Based on limited published data, few clinical recommendations can be made regarding prevention, evaluation and management of this trouble. Longitudinal studies must be conducted to evaluate its real impact on quality of life.
